MedDataX Logo

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

NCT ID: NCT04002349

Last Updated: 2019-06-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-01

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Determination of the Efficacy of Different Medications for Idiopathic Rhinitis Impact of Different Medications on Biomarkers of Idiopathic Rhinitis Safety and Tolerance of Different Medications for Idiopathic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A: Placebo group

Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning

Group Type PLACEBO_COMPARATOR

0.9% natural saline

Intervention Type DRUG

Detailed in arm descriptions

B: Budesonide Nasal Spray (Rhinocort)

Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning

Group Type EXPERIMENTAL

Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Intervention Type DRUG

Detailed in arm descriptions

C: Levocabastine Nasal Spray (Livostine)

Treated by Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning

Group Type EXPERIMENTAL

Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Intervention Type DRUG

Detailed in arm descriptions

D: Combined Treatment

Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning

Group Type EXPERIMENTAL

Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Intervention Type DRUG

Detailed in arm descriptions

Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Intervention Type DRUG

Detailed in arm descriptions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Detailed in arm descriptions

Intervention Type DRUG

Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Detailed in arm descriptions

Intervention Type DRUG

0.9% natural saline

Detailed in arm descriptions

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Not younger than 18 years old
* Diagnosed as idiopathic rhinitis
* Signed and volunteered for the study

Exclusion Criteria

* Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps
* Allergic to the medicines about to study
* Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Institute of Otolaryngology

UNKNOWN

Sponsor Role collaborator

Shanghai Johnson & Johnson Pharmaceuticals, Ltd.

UNKNOWN

Sponsor Role collaborator

Beijing Tongren Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Tongren Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Yifan Meng

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Luo Zhang, M.D.

Role: primary

Yifan Meng, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TR-Med-NAR-Cluster

Identifier Type: -

Identifier Source: org_study_id